Novo Nordisk said Wednesday that demand for its Wegovy pill got off to a strong start after it launched in the U.S. in early January. By Jan. 23 — less than three weeks after it became available — ...

In another move to broaden its offerings, Abrams has announced the creation of its first commercial adult fiction imprint, akaStory, which will launch in January 2027 with six novels on its inaugural ...

During a contentious Senate hearing in the morning and a later press conference, lawmakers and anti-abortion groups challenged the Food and Drug Administration to roll back Biden-era policies that ...

Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection. Patients with a prescription could obtain the starter 1.5 mg dose of the tablet ...

Americans can now purchase a starter dose of Novo Nordisk’s weight loss drug Wegovy in pill form, the company announced Monday, pledging widespread availability. The 1.5 milligram starter dose of a ...

The U.S. Food and Drug Administration (FDA) has approved its first oral glucagon-like peptide (GLP)-1 pill for weight management, a news release from Novo Nordisk announced on Monday. The pill, Wegovy ...

The Food and Drug Administration has approved the first GLP-1 pill for weight loss, its manufacturer Novo Nordisk announced Monday, a milestone in the growth of the revolutionary drugs. The drug, a ...

Weight-loss pills that harness the same mechanism as the wildly popular drugs Wegovy and Ozempic are coming to the U.S. On Monday Novo Nordisk announced that the U.S. Food and Drug Administration ...

Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking Wegovy and Zepbound injections in a late-stage trial ...

Fintech startup Imprint Payments Inc., which helps retailers like Brooks Brothers offer co-branded credit cards, has reached a valuation of $1.2 billion in a new funding round led by Khosla Ventures.

This content has been selected, created and edited by the Finextra editorial team based upon its relevance and interest to our community. The round was led by Khosla Ventures, with participation from ...

Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by ...